Author Question: Which of the following statements about H. erectus fossils is NOT true? A. They had a thicker ... (Read 11 times)

jwb375

  • Hero Member
  • *****
  • Posts: 540
Which of the following statements about H. erectus fossils is NOT true?
 
  A. They had a thicker skull bone and a very robust skeleton.
  B. They indicate increasing hunting proficiency.
  C. They are often found associated with Acheulean stone tools.
  D. They have hyperrobust chewing muscles and broad, flat molars.
  E. They show an increasing reliance on cultural adaptation.

Question 2

Which of the following statements about the appearance of H. habilis is true?
 
  A. H. habilis evolved from Paranthropus boisei, the hyperrobust australopith.
  B. H. habilis demonstrates the adaptive advantage of sedentism.
  C. H. habilis was relatively small in stature compared to H. erectus.
  D. H. habilis shows evidence of a shift from an arboreal to an open-grassland environment.
  E. H. habilis represents a gradual shift away from predation to vegetarianism.



ju

  • Sr. Member
  • ****
  • Posts: 325
Answer to Question 1

Answer: D

Answer to Question 2

Answer: C



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Signs and symptoms of a drug overdose include losing consciousness, fever or sweating, breathing problems, abnormal pulse, and changes in skin color.

Did you know?

Of the estimated 2 million heroin users in the United States, 600,000–800,000 are considered hardcore addicts. Heroin addiction is considered to be one of the hardest addictions to recover from.

Did you know?

Only one in 10 cancer deaths is caused by the primary tumor. The vast majority of cancer mortality is caused by cells breaking away from the main tumor and metastasizing to other parts of the body, such as the brain, bones, or liver.

Did you know?

After 5 years of being diagnosed with rheumatoid arthritis, one every three patients will no longer be able to work.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library